Rad Net, Inc. RDNT
We take great care to ensure that the data presented and summarized in this overview for RadNet, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RDNT
View all-
Black Rock Inc. New York, NY9.61MShares$720 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.39MShares$554 Million0.01% of portfolio
-
Beck Mack & Oliver LLC New York, NY3.26MShares$245 Million4.12% of portfolio
-
Rtw Investments, LP New York, NY2.69MShares$202 Million2.35% of portfolio
-
State Street Corp Boston, MA2.48MShares$186 Million0.01% of portfolio
-
Allspring Global Investments Holdings, LLC1.8MShares$135 Million0.19% of portfolio
-
Geode Capital Management, LLC Boston, MA1.64MShares$123 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA1.63MShares$122 Million0.02% of portfolio
-
Jb Capital Partners LP Armonk, NY1.47MShares$111 Million17.3% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.41MShares$106 Million0.02% of portfolio
Latest Institutional Activity in RDNT
Top Purchases
Top Sells
About RDNT
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Insider Transactions at RDNT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 11
2025
|
Cornelis Wesdorp Pres & CEO, Digital Health |
SELL
Open market or private sale
|
Direct |
500
-0.93%
|
$36,000
$72.13 P/Share
|
|
Sep 11
2025
|
David Jeffrey Katz EVP and Chief Legal Officer |
SELL
Bona fide gift
|
Direct |
4,593
-5.29%
|
-
|
|
Sep 10
2025
|
Norman R Hames Pres and COO-West Operations |
SELL
Open market or private sale
|
Direct |
10,000
-4.01%
|
$720,000
$72.74 P/Share
|
|
Sep 09
2025
|
Cornelis Wesdorp Pres & CEO, Digital Health |
SELL
Open market or private sale
|
Direct |
500
-0.92%
|
$35,500
$71.99 P/Share
|
|
Aug 27
2025
|
Norman R Hames Pres and COO-West Operations |
SELL
Open market or private sale
|
Indirect |
5,000
-20.09%
|
$355,000
$71.1 P/Share
|
|
Aug 19
2025
|
Ranjan Jayanathan Chief Information Officer |
SELL
Open market or private sale
|
Direct |
65,598
-32.19%
|
$4,395,066
$67.5 P/Share
|
|
Aug 19
2025
|
Cornelis Wesdorp Pres & CEO, Digital Health |
SELL
Open market or private sale
|
Direct |
1,500
-2.68%
|
$99,000
$66.98 P/Share
|
|
Aug 13
2025
|
David Jeffrey Katz EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
17,000
-16.38%
|
$1,156,000
$68.31 P/Share
|
|
Jun 17
2025
|
Alma Gregory Sorenson EVP, Chief Science Officer |
SELL
Bona fide gift
|
Direct |
5,600
-0.48%
|
-
|
|
Jun 10
2025
|
Laura Pastre Jacobs Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,699
+9.09%
|
-
|
|
Jun 10
2025
|
Lawrence L Levitt Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,699
+1.58%
|
-
|
|
Jun 10
2025
|
Gregory E. Spurlock Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,699
+33.78%
|
-
|
|
Jun 10
2025
|
David L Swartz Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,699
+1.5%
|
-
|
|
Jun 05
2025
|
Michael N Murdock EVP, Mergers and Acquisitions |
SELL
Open market or private sale
|
Direct |
11,132
-20.53%
|
$645,656
$58.05 P/Share
|
|
Jun 01
2025
|
Alma Gregory Sorenson EVP, Chief Science Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,436
+0.88%
|
-
|
|
May 23
2025
|
Alma Gregory Sorenson EVP, Chief Science Officer |
SELL
Open market or private sale
|
Direct |
55,000
-4.52%
|
$3,080,000
$56.48 P/Share
|
|
May 22
2025
|
Alma Gregory Sorenson EVP, Chief Science Officer |
SELL
Open market or private sale
|
Direct |
45,000
-3.57%
|
$2,565,000
$57.06 P/Share
|
|
May 16
2025
|
Lawrence L Levitt Director |
SELL
Open market or private sale
|
Direct |
5,000
-2.94%
|
$305,000
$61.09 P/Share
|
|
May 16
2025
|
Stephen M Forthuber Pres & COO-Eastern Operations |
SELL
Open market or private sale
|
Direct |
18,820
-3.4%
|
$1,129,200
$60.34 P/Share
|
|
May 15
2025
|
Norman R Hames Pres and COO-West Operations |
SELL
Open market or private sale
|
Indirect |
2,911
-10.47%
|
$174,660
$60.0 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 379K shares |
|---|---|
| Exercise of conversion of derivative security | 147K shares |
| Bona fide gift | 18.2K shares |
|---|---|
| Open market or private sale | 339K shares |
| Other acquisition or disposition | 250K shares |